Evaluation of anesthesia effect and safety of different dosages of esketamine combined with propofol during hysteroscopic surgery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400092022

Enrollment

Unknown

Registered

2024-11-07

Start date

2022-10-06

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hysteroscopic s surgery

Interventions

K1 group:0.15mg/kg esketamine induction

K2 group:0.3mg/kg esketamine induction

K3group:0.5mg/kg esketamine induction

S group:0.1µg/kg sufentanil induction

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1)Aged 18-60 years old; (2)BMI:18.5-23.9kg/m^2; (3)ASA I-II level; (4)Indications for hysteroscopic surgery

Exclusion criteria

Exclusion criteria: (1)Significant disease of cardiovascular system and respiratory system; (2) Severe hyperthyroidism; (3)History of psychological problems or psychiatric disease; (4)Excessive drinking and smoking; (5)Uterus malformation or cervical canal malformation/stenosis; (6)intrauterine adhesion that may make hysteroscopy difficult to.

Design outcomes

Primary

Measure	Time frame
NRS;dosage of propofol;	—

Secondary

Measure	Time frame
blood pressure;heart rate;saturation of pulse oximetry;awakening time;adverse reaction;	—

Countries

China

Contacts

Public ContactRuru Li

Wenzhou People's Hospital

736800713@qq.com+86 150 6781 2381

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 30, 2026